# Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

> **NCT02684591** · PHASE2 · COMPLETED · sponsor: **University of California, San Diego** · enrollment: 50 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease
- HIV

## Interventions

- **DRUG:** Aramchol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02684591
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684591, "Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02684591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*